Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2009

View Archived Issues

Novel KSP inhibitors discovered by 4SC for cancer treatment

Bayer Schering Pharma discloses A1 receptor agonists for cardiovascular and other disorders

Santhera completes enrollment in RHODOS clinical study of Catena in LHON

Vical and Teva sign agreement for sales and marketing of Allovectin-7 in Israel

Invega approved for the treatment of schizoaffective disorder

Novel nucleotide analogues described by Alios Biopharma

Palau Pharma developing novel histamine H4 receptor antagonists

Novel antibacterial agents in early development at Shionogi

Debiopharm and MSM sign development and commercialization agreement for Debio-0929

Kringle concludes dosing and safety evaluation in phase Ia trial of rhHGF in renal disease

Human embryonic stem cell-derived motor neuron progenitors for clinical application

EMD-273063 shows biological activity in phase I/II trial in metastatic malignant melanoma

Lexicon initiates phase II clinical trial of S1P inhibitor LX-2931 in RA

FDA grants orphan drug designation to DOR's orBec for chronic gastrointestinal GVHD

Monotherapy data reported for lersivirine in HIV-1 infected subjects

BI-2536 monotherapy shows no activity in phase II trial in patients with SCLC

Fuso and OncoTherapy initiate phase II study of OTS-102 for biliary cancer

Deferoxamine reduces brain edema and neuronal death in a rat model of SAH

NeuroSearch completes preclinical development of GABA-A receptor modulator NSD-721

FDA approves SPA for Keryx's phase III trial of perifosine in multiple myeloma

Bionovo reports results from phase Ib clinical trial of Bezielle in advanced breast cancer

Napo completes dose selection stage of ADVENT trial of crofelemer in HIV/AIDS

Adventrx to submit an NDA for vinorelbine emulsion by the end of 2009

EpiCept files Ceplene NDS with Health Canada for AML patients in first complete remission

Nile initiates dosing in phase II clinical study of CD-NP for acute heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...